| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Beaucage reagent is used as a reagent for DNA cleavage. It is a DNA/RNA synthesis reagent. It has also been identified as a potent inhibitor of platelet aggregation and has been used as an anti-inflammatory and anti-thrombotic agent.
|
|---|---|
| ln Vitro |
In vitro, Beaucage reagent is potent in causing DNA cleavage, acting through a thiol-dependent mechanism. This property is utilized in the synthesis and modification of oligonucleotides, particularly for introducing phosphorothioate linkages.
|
| ln Vivo |
In vivo activity of Beaucage reagent is not well-characterized, as its primary use is as a chemical reagent for in vitro nucleic acid research. Its potential anti-inflammatory and anti-thrombotic activities have been noted but are not the primary focus of its application.
|
| Enzyme Assay |
Cell-free DNA cleavage assays are performed using purified DNA oligonucleotides and Beaucage reagent. The reagent is incubated with the DNA under various conditions, and the cleavage products are analyzed by gel electrophoresis or HPLC to assess its DNA-cleaving activity and mechanism.
|
| Cell Assay |
In vitro cellular assays for Beaucage reagent are limited, as it is primarily used as a chemical reagent. However, its DNA-cleaving activity could be studied in cell-based systems to evaluate its potential for inducing DNA damage and apoptosis. Such studies would involve treating cells with the reagent and measuring DNA fragmentation and cell viability.
|
| Animal Protocol |
In vivo animal experiments for Beaucage reagent are not well-documented, as the compound is primarily used as a research chemical rather than a therapeutic agent. Its use is limited to in vitro biochemical and nucleic acid research applications.
|
| ADME/Pharmacokinetics |
Beaucage reagent (C7H4O3S2) has a molecular weight of 200.23 g/mol. It is soluble in DMSO (10 mM). It is a white solid. Storage conditions typically involve keeping the compound at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
The toxicity of Beaucage reagent is related to its DNA-cleaving activity. It is considered a potent DNA cleavage agent and should be handled with appropriate safety precautions. Detailed toxicological data are limited to its use as a research chemical.
|
| Additional Infomation |
Beaucage reagent is a potent DNA cleavage agent used for preparing phosphorothioate oligomers. It is also known as 3H-1,2-Benzodithiol-3-one-1,1-dioxide. It has been identified as a potent inhibitor of platelet aggregation and has been used as an anti-inflammatory and anti-thrombotic agent. It is a DNA/RNA synthesis reagent.
|
| Molecular Formula |
C7H4O3S2
|
|---|---|
| Molecular Weight |
200.2349
|
| Exact Mass |
199.96
|
| CAS # |
66304-01-6
|
| PubChem CID |
3009847
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
414.6±28.0 °C at 760 mmHg
|
| Melting Point |
103-107 °C(lit.)
|
| Flash Point |
204.6±24.0 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
1.13
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1(C2=C([H])C([H])=C([H])C([H])=C2C(=O)S1)(=O)=O
|
| InChi Key |
JUDOLRSMWHVKGX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H4O3S2/c8-7-5-3-1-2-4-6(5)12(9,10)11-7/h1-4H
|
| Chemical Name |
1,1-dioxo-1λ6,2-benzodithiol-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~499.43 mM)
H2O : ~0.14 mg/mL (~0.70 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (12.49 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (12.49 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9943 mL | 24.9713 mL | 49.9426 mL | |
| 5 mM | 0.9989 mL | 4.9943 mL | 9.9885 mL | |
| 10 mM | 0.4994 mL | 2.4971 mL | 4.9943 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
